
IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort businesswire.com/news/home/2…

IntraBio is a late-stage biopharmaceutical company developing novel therapies for rare (“orphan”) and common neurodegenerative diseases

IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort businesswire.com/news/home/2…

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) accesswire.com/660477/IntraB…

IntraBio Appoints Jim Meyers as President and CEO accesswire.com/618176/IntraB…

Professor Michael Strupp Receives the 2020 Galenus-von-Pergamon Award accesswire.com/viewarticle.a…

IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…

New hope for Treatment Against Niemann-Pick disease Type C businessnewstribune.com/2020… via @Business News Tribune

"IntraBio Reports Positive Data from NPC Study" - @GlobalGenes globalgenes.org/2020/10/06/i…

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…

JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: https://t.co/DEbdE5Ybh6 #NPC #niemannpick #nnpdf

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease #IntraBio #Ataxia #FDA #Biotech accesswire.com/538752/IntraB…

IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease #IntraBio #MHRA #NPC accesswire.com/538583/IntraB…

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease #Biotech #FDA #IntraBio #IND accesswire.com/535211/IntraB…

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease #Biotech #FDA #IntraBio accesswire.com/534958/IntraB…

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 #RareDisease #Biotech #IntraBio accesswire.com/532110/IntraB…

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 #RareDisease #FDA #Biotech #IntraBio accesswire.com/530834/IntraB…

IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA #RareDisease #Biotech #IntraBio accesswire.com/530328/IntraB…